CY1112650T1 - Αζιθρομυκινη για την θεραπεια οζωδους ακμης - Google Patents

Αζιθρομυκινη για την θεραπεια οζωδους ακμης

Info

Publication number
CY1112650T1
CY1112650T1 CY20121100054T CY121100054T CY1112650T1 CY 1112650 T1 CY1112650 T1 CY 1112650T1 CY 20121100054 T CY20121100054 T CY 20121100054T CY 121100054 T CY121100054 T CY 121100054T CY 1112650 T1 CY1112650 T1 CY 1112650T1
Authority
CY
Cyprus
Prior art keywords
azithromycin
nodular acne
acne therapy
therapy
nodular
Prior art date
Application number
CY20121100054T
Other languages
Greek (el)
English (en)
Inventor
David Wade Osborne
Gordon Jay Dow
Bhaskar Chaudhuri
Barry Calvarese
Original Assignee
Dow Pharmaceutical Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dow Pharmaceutical Sciences filed Critical Dow Pharmaceutical Sciences
Publication of CY1112650T1 publication Critical patent/CY1112650T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Saccharide Compounds (AREA)
CY20121100054T 2006-10-03 2012-01-17 Αζιθρομυκινη για την θεραπεια οζωδους ακμης CY1112650T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84906506P 2006-10-03 2006-10-03
US11/635,127 US7704959B2 (en) 2006-10-03 2006-12-06 Azithromycin for the treatment of nodular acne
EP07838730A EP2086552B1 (en) 2006-10-03 2007-09-24 Azithromycin for the treatment of nodular acne

Publications (1)

Publication Number Publication Date
CY1112650T1 true CY1112650T1 (el) 2016-02-10

Family

ID=39261797

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20121100054T CY1112650T1 (el) 2006-10-03 2012-01-17 Αζιθρομυκινη για την θεραπεια οζωδους ακμης

Country Status (18)

Country Link
US (2) US7704959B2 (enExample)
EP (2) EP2086552B1 (enExample)
JP (1) JP2010505827A (enExample)
KR (1) KR20090064592A (enExample)
CN (2) CN102614210A (enExample)
AT (1) ATE533496T1 (enExample)
AU (1) AU2007302663B2 (enExample)
BR (1) BRPI0719535A2 (enExample)
CA (1) CA2664673A1 (enExample)
CY (1) CY1112650T1 (enExample)
DK (1) DK2086552T3 (enExample)
ES (2) ES2574677T3 (enExample)
MX (1) MX2009003484A (enExample)
PL (2) PL2086552T3 (enExample)
PT (1) PT2086552E (enExample)
RU (1) RU2009116629A (enExample)
SI (1) SI2086552T1 (enExample)
WO (1) WO2008042139A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8143227B2 (en) * 2007-09-05 2012-03-27 Dow Pharmaceutical Sciences, Inc. Azithromycin for treatment of skin disorders
US8124123B2 (en) * 2007-09-05 2012-02-28 Dow Pharmaceutical Sciences, Inc. Controlled release azithromycin solid dosages forms
CN107281155B (zh) * 2017-06-06 2020-04-10 扬子江药业集团四川海蓉药业有限公司 一种阿奇霉素片及其制备方法
CA3070663A1 (en) * 2017-07-21 2019-01-24 Almirall, Llc Treatment of non-inflammatory lesions

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU43006B (en) 1981-03-06 1989-02-28 Pliva Pharm & Chem Works Process for preparing n-methyl-11-aza-10-deoxo-10-dihydro erythromycin and derivatives thereof
US4474758A (en) 1981-11-19 1984-10-02 American Cyanamid Company Haemophilus influenzae type b and pertussis outer membrane component combined vaccine
US4474768A (en) 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
US4474766A (en) 1983-06-27 1984-10-02 Merck & Co., Inc. Anti-inflammatory/analgesic combination of cyclo-(N-methyl-Ala-Tyr-D-Trp-Lys-Val-Phe) and a selected non-steroidal anti-inflammatory drug (NSAID)
MX12213A (es) 1987-07-09 1993-05-01 Pfizer Metodo de preparacion de dihidrato de azitromicina cristalino
FR2710841B1 (fr) * 1993-10-05 1995-11-17 Oreal Composition cosmétique ou pharmaceutique pour la peau, anhydre et stable, à base de rétinol et son utilisation en vue du traitement des maladies de la peau.
GB9723669D0 (en) * 1997-11-07 1998-01-07 Univ Aberdeen Skin penetration enhancing components
US7211267B2 (en) 2001-04-05 2007-05-01 Collagenex Pharmaceuticals, Inc. Methods of treating acne
EP1716856A3 (en) * 2001-04-05 2009-02-18 Collagenex Pharmaceuticals, Inc. The treatment of acne
HRP20010301A2 (en) * 2001-04-27 2001-12-31 Pliva D D New therapeutic indication for azithromycin in the treatment of non-infective inflammatory diseases
US9035741B2 (en) * 2003-06-27 2015-05-19 Stryker Corporation Foot-operated control console for wirelessly controlling medical devices

Also Published As

Publication number Publication date
ES2377470T3 (es) 2012-03-27
US7704959B2 (en) 2010-04-27
RU2009116629A (ru) 2010-11-10
MX2009003484A (es) 2009-10-26
PT2086552E (pt) 2011-12-19
SI2086552T1 (sl) 2012-01-31
EP2420240A1 (en) 2012-02-22
PL2420240T3 (pl) 2016-10-31
ES2574677T3 (es) 2016-06-21
CN101534837A (zh) 2009-09-16
JP2010505827A (ja) 2010-02-25
US20100216732A1 (en) 2010-08-26
WO2008042139A3 (en) 2008-10-16
CN101534837B (zh) 2012-04-04
EP2086552B1 (en) 2011-11-16
DK2086552T3 (da) 2012-01-09
CN102614210A (zh) 2012-08-01
BRPI0719535A2 (pt) 2014-01-14
CA2664673A1 (en) 2008-04-10
KR20090064592A (ko) 2009-06-19
EP2420240B1 (en) 2016-05-11
AU2007302663B2 (en) 2012-07-12
WO2008042139A2 (en) 2008-04-10
PL2086552T3 (pl) 2012-03-30
ATE533496T1 (de) 2011-12-15
HK1130667A1 (en) 2010-01-08
US20080081790A1 (en) 2008-04-03
AU2007302663A1 (en) 2008-04-10
EP2086552A4 (en) 2009-11-04
EP2086552A2 (en) 2009-08-12

Similar Documents

Publication Publication Date Title
NO2018023I1 (enExample)
NO20091661L (no) Anvendelse av pegylert IL-10 for a behandle kreft
CO5570678A2 (es) N-alquilo-4-metileneamino-3-hidroxilo-2-piridonas como anti- microbianos
CY1110889T1 (el) C-αρυλο γλυκοζιτικοι sglt2 αναστολεις και μεθοδος για την παραγωγη τους
MX2007000611A (es) Tratamiento de la piel con luz y un agente benefico para mitigar el acne.
WO2009156735A3 (en) New therapeutic agents
TW200738725A (en) Unsaturated mTOR inhibitors
DOP2010000302A (es) Antagonistas de la trayectoria hedgehog de ftalazina disustituida
JP2011528636A5 (enExample)
WO2006135789A3 (en) Fiber-coupled single photon source
SI2086552T1 (sl) Azitromicin za zdravljenje nodularnih aken
IL229594A0 (en) Materials and preparations for the treatment of tumors
NO20092496L (no) Ny terapeutisk anvendelse for behandling av leukemi
ATE423294T1 (de) Beleuchtungsvorrichtung mit reduziertem platzbedarf
MX2009009777A (es) Administracion intravesical de apaziquone despues de reseccion transuretral para tratamiento de cancer.
WO2007044679A3 (en) Treating metabolic syndrome with 2-deoxy-d-glucose
UA38980U (ru) Способ местного лечения розовых угрей
UA2826U (uk) Спосіб лікування розсіяного склерозу
UA29550U (en) Compound 1-(1',1'-difluoro-2'-bromo-2'-chloroethyl)-5-bromouracil with potential physiological properties